Global Information
회사소개 | 문의 | 위시리스트

집먼지 진드기 알레르기 : 세계 임상시험 리뷰

House Dust Mite Allergy Global Clinical Trials Review, H2, 2018

리서치사 GlobalData
발행일 2018년 07월 상품 코드 318337
페이지 정보 영문 95 Pages
가격
US $ 2,500 ₩ 2,987,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,974,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,961,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


집먼지 진드기 알레르기 : 세계 임상시험 리뷰 House Dust Mite Allergy Global Clinical Trials Review, H2, 2018
발행일 : 2018년 07월 페이지 정보 : 영문 95 Pages

집먼지 진드기 알레르기는 집먼지 진드기에 의해 생성되는 알레르기 유발 물질에 대한 알레르기 반응입니다.

집먼지 진드기 알레르기(House Dust Mite Allergy) 치료제 임상시험에 대해 조사 분석했으며, 임상시험 건수 및 피험자수, 단계(상)별, 진행 상황별 임상시험 동향, 유망 기업, 개발중인 치료제, 임상시험 개요 등의 정보를 전해드립니다.

목차

서론

지역별 임상시험

  • 국가별 임상시험 동향
    • 아시아태평양 지역 주요 국가
    • 유럽 주요 국가
    • 북미 주요 국가
    • 중남미 주요 국가

G7 국가의 임상시험 : 면역계 임상시험에 대한 집먼지 진드기 알레르기의 비율

G7 국가의 임상시험 : 단계(상)별

G7 국가의 임상시험 : 진행 상황별

E7 국가의 임상시험 : 면역계 임상시험에 대한 집먼지 진드기 알레르기의 비율

E7 국가의 임상시험 : 단계(상)별

E7 국가의 임상시험 : 진행 상황별

단계(상)별 임상시험

진행 상황별 임상시험

평가 항목별 임상시험

미완료 임상시험

일정기간에 채용된 피험자

스폰서 종류별 임상시험

유망한 스폰서

  • 집먼지 진드기 알레르기 치료제 임상시험에 참여하고 있는 주요 기업

유망한 치료제

임상시험 개요

  • 주요 기업의 임상시험 개요
    • ALK-Abello A/S
    • Stallergenes S.A.
    • Merck & Co., Inc.
    • Circassia Holdings Ltd.
    • Laboratorios LETI S.L.
    • Japan Tobacco Inc.
    • Cytos Biotechnology AG (휴지중)
    • Merck KGaA
    • Lofarma S.p.A.
    • Anergis SA
  • 주요 대학, 연구기관 및 병원의 임상시험 개요
    • Medical University of Lodz
    • Johann Wolfgang Goethe University Hospitals
    • Universitaire Ziekenhuizen Leuven
    • Academic Medical Center
    • Ankara University
    • Aalborg University
    • University of South Florida
    • Medical University of Silesia
    • Bayside Health
    • Medical University of Vienna

주요 임상 개요

부록

도표

KSM 14.11.21

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • House Dust Mite Allergy Therapeutics, Global, Clinical Trials by Region, 2018* 6
  • House Dust Mite Allergy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 7
  • House Dust Mite Allergy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 8
  • House Dust Mite Allergy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 9
  • House Dust Mite Allergy Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 10
  • House Dust Mite Allergy Therapeutics Clinical Trials, North America, Top Countries, 2018* 11
  • House Dust Mite Allergy Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2018* 12
  • House Dust Mite Allergy Therapeutics Clinical Trials, Central and South America, Top Countries, 2018* 13
  • Proportion of House Dust Mite Allergy to Immunology Clinical Trials, G7 Countries (%), 2018* 14
  • House Dust Mite Allergy Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 15
  • House Dust Mite Allergy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 16
  • Proportion of House Dust Mite Allergy to Immunology Clinical Trials, E7 Countries (%), 2018* 17
  • House Dust Mite Allergy Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 18
  • House Dust Mite Allergy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 19
  • House Dust Mite Allergy Therapeutics, Global, Clinical Trials by Phase, 2018* 20
  • House Dust Mite Allergy Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 21
  • House Dust Mite Allergy Therapeutics, Global, Clinical Trials by Trial Status, 2018* 22
  • House Dust Mite Allergy Therapeutics Clinical Trials, Global, by End Point Status, 2018* 23
  • House Dust Mite Allergy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 24
  • House Dust Mite Allergy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 25
  • House Dust Mite Allergy Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 26
  • House Dust Mite Allergy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 27
  • House Dust Mite Allergy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 28

List of Figures

  • House Dust Mite Allergy Therapeutics, Global, Clinical Trials by Region (%), 2018* 6
  • House Dust Mite Allergy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 7
  • House Dust Mite Allergy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 8
  • House Dust Mite Allergy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 9
  • House Dust Mite Allergy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 10
  • House Dust Mite Allergy Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 11
  • House Dust Mite Allergy Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2018* 13
  • Proportion of House Dust Mite Allergy to Immunology Clinical Trials, G7 Countries (%), 2018* 14
  • House Dust Mite Allergy Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 15
  • House Dust Mite Allergy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 16
  • Proportion of House Dust Mite Allergy to Immunology Clinical Trials, E7 Countries (%), 2018* 17
  • House Dust Mite Allergy Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 18
  • House Dust Mite Allergy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 19
  • House Dust Mite Allergy Therapeutics, Global, Clinical Trials by Phase (%), 2018* 20
  • House Dust Mite Allergy Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 21
  • House Dust Mite Allergy Therapeutics, Global, Clinical Trials by Trial Status, 2018* 22
  • House Dust Mite Allergy Therapeutics Clinical Trials, Global, by End Point Status, 2018* 23
  • House Dust Mite Allergy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 24
  • House Dust Mite Allergy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 25
  • House Dust Mite Allergy Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 26
  • House Dust Mite Allergy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 27
  • House Dust Mite Allergy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 28
  • GlobalData Methodology 94

GlobalData's clinical trial report, "House Dust Mite Allergy Global Clinical Trials Review, H2, 2018" provides an overview of House Dust Mite Allergy clinical trials scenario. This report provides top line data relating to the clinical trials on House Dust Mite Allergy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 3
  • Report Guidance 4
  • GlobalData Clinical Trials Report Coverage 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Top Countries Contributing to Clinical Trials in Central and South America 13
  • Clinical Trials by G7 Countries: Proportion of House Dust Mite Allergy to Immunology Clinical Trials 14
  • Clinical Trials by Phase in G7 Countries 15
  • Clinical Trials in G7 Countries by Trial Status 16
  • Clinical Trials by E7 Countries: Proportion of House Dust Mite Allergy to Immunology Clinical Trials 17
  • Clinical Trials by Phase in E7 Countries 18
  • Clinical Trials in E7 Countries by Trial Status 19
  • Clinical Trials by Phase 20
  • In Progress Trials by Phase 21
  • Clinical Trials by Trial Status 22
  • Clinical Trials by End Point Status 23
  • Subjects Recruited Over a Period of Time 24
  • Clinical Trials by Sponsor Type 25
  • Prominent Sponsors 26
  • Top Companies Participating in House Dust Mite Allergy Therapeutics Clinical Trials 27
  • Prominent Drugs 28
  • Latest Clinical Trials News on House Dust Mite Allergy 29
  • May 29, 2018: Allergy Therapeutics - Positive new data with house-dust mite immunotherapy 29
  • Clinical Trial Profile Snapshots 30

Appendix 93

  • Abbreviations 93
  • Definitions 93
  • Research Methodology 94
  • Secondary Research 94
  • About GlobalData 95
  • Contact Us 95
  • Source 95
Back to Top
전화 문의
F A Q